CD274 and cancer: EBV-positive/PD-L1-positive cancers demonstrated a prognosis similar to EBV-negative/PD-L1-negative cases (OS: HR, 1.08; 95% CI, 0.81-1.45; p = 0.59).<h4>Conclusions</h4>In metastatic disease, MSI and EBV status were not associated with significant prognostic effects.